We Are Crinetics

Crinetics is a pharmaceutical company founded in endocrinology research. Our intense focus is on developing much-needed therapies for people with rare endocrine diseases. For us, it’s all about these underserved patients, who are eager to find therapies that provide effective disease control and bring more simplicity to their lives.

To better achieve these goals, we also partner with endocrinologists and other healthcare practitioners to ensure we’re solving real problems for them.

An Entire Pipeline of Progress

Intellectual rigor, sound science, and innovative approaches are the hallmarks of our work and the way we maintain a healthy pipeline.

We focus on the discovery of drugs for rare endocrine disease and related tumors with:

  • High unmet medical need
  • Established biology
  • Biomarker endpoints
  • Early phase POC
  • Efficient registration trials
View Pipeline >
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company

NANETS 2021

Dose selection for paltusotine, a once-daily, oral, nonpeptide, somatostatin receptor 2 ligand (SST2), for the treatment of patients with carcinoid syndrome (CS)

Poster

Presentation

hjalmar 350x450 uai

Paltusotine phase 2 study in carcinoid syndrome

Fill out this form to be contacted by a member of our study team.